A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors von Drilon, A, Marwan, F, Fu, S, Patel, M.R, Olszanski, A.J, Lockhart, A.C, Liu, S.V, Bazhenova, L, Seery, T, Nikolinakos, P, Patel, R, Oliver, J.W, Multani, P.S, Wang, D

Volltext

300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma von Rasco, D.W, Middleton, M.R, Gonzalez, R, Corrie, P, Pavlick, A, Lorigan, P, Plummer, R, Gore, M, Herbert, C, Agarwala, S.S, Logan, T.F, Khleif, S.N, Papadopoulos, K.P, Rangachari, L, Suri, A, Xu, Q, Kneissl, M, Bozón, V, Olszanski, A.J

Volltext

24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma von Long, G.V, Dummer, R, Ribas, A, Puzanov, I, Michielin, O, Vanderwalde, A, Andtbacka, R.H.I, Cebon, J, Fernandez, E, Malvehy, J, Olszanski, A.J, Gajewski, T.F, Kirkwood, J.M, Gause, C, Chen, L, Kaufman, D.R, Chou, J, Hodi, F.S

Volltext

364 First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutan... von Middleton, M, Rasco, D.W, Olszanski, A.J, Corrie, P, Lorigan, P, Plummer, R, Larkin, J, Pavlick, A, Zhou, X, Yuan, Z, Gangolli, E, Kneissl, M, Bozón, V, Gonzalez, R

Volltext

324 Clinical pharmacokinetics (PK), translational PK/pharmacodynamics (PD), and exposure–adverse events (AEs) relationship of MLN2480, an oral investigational pan-RAF kinase inhibi... von Zhou, X, Olszanski, A.J, Middleton, M, Gonzalez, R, Bargfrede, M.J, Kneissl, M, Bozón, V, Gangolli, E, Venkatakrishnan, K, Patel, M, Zopf, C, Rasco, D.W

Volltext

1077TiP TAK-500 as a single agent and in combination with pembrolizumab in patients (pts) with advanced solid tumors: Rationale and design of a phase I/II study von Singh, H., Diamond, J.R., Henry, J.T., Olszanski, A.J., Rasco, D., Patel, S.P., Gregory, R., Appleman, V.A., Gibbs, J.P., Zhang, W., Wang, C.I., Parent, A.A., Chung, V.

Volltext

598TiP A phase I/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumours von Luke, J.J., Janku, F., Strauss, J., Olszanski, A.J., Leach, K., Radhakrishnan, I., Abbas, A.

Volltext

996MO Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: Data from phase I dose escalation von Luke, J.J., Gao, X., Olszanski, A.J., Sanborn, R.E., Falchook, G.S., Patel, S., Bedard, P.L., Orr, D., Gibbs, J.P., Li, C., Huang, Y-C., Gregory, R., Ramesh, R., Xu, R., Wu, B., Ding, K., Raizer, J., Lorusso, P.

Volltext

Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate a... von Saggu, G., Stroopinsky, D., Dudek, A.Z., Olszanski, A.J., Juric, D., Dowlati, A., Vaishampayan, U., Assad, H., Rodón, J., Gibbs, J., Green, J., Du, Z., Rudicell, R., Kannan, K., Gharavi, R., Gomez-Pinillos, A., Fram, R.J., Berger, A., Sachsenmeier, K., Kasar, S.

Volltext

1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumo... von Olszanski, A.J., Luke, J.J., LoRusso, P.M., Falchook, G.S., Bedard, P.L., Sanborn, R.E., Patel, S.P., Orr, D., Gibbs, J.P., Li, C., Huang, Y-C., Gregory, R., Perera, S., Xu, R., Joshi, A., Lee, M.Y., Raizer, J., Gao, X.

Volltext

P4.11D.04 A Phase 1/2 Study of REGN7075 (EGFRÃ-CD28) Combined with Cemiplimab (anti-PD-1) In NSCLC: Trial in Progress Update von Johnson, M.L., Girda, E., Sohal, D., Lakhani, N.J., Olszanski, A.J., Fong, L., Kinnaman, M., Han, H., Moesta, A., Hao, Y., Li, S., Ganguly, S., Seebach, F., Mathias, M., Segal, N.H.

Volltext

1083P A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma von Shoushtari, A.N., Olszanski, A.J., Nyakas, M., Hornyak, T.J., Wolchok, J.D., Levitsky, V., Møller, A-S., Kuryk, L., Risberg Handeland, K., Jäderberg, M.

Volltext

1006P Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (... von De Miguel, M., Landa Magdalena, A., Moreno Garcia, V., Gambardella, V., Menis, J., Daniele, G., El-Khoueiry, A.B., Spira, A.I., Gravina, A., Olszanski, A.J., Rapaic, O., Li, J., Poullain, H., Margall, G., Wong, G., Hedrich, W., Russella Pollard, J., Gan, J., Shi, X., Andtbacka, R.H.I.

Volltext

Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037 von Gangadhar, T.C., Hamid, O., Smith, D.C., Bauer, T.M., Wasser, J.S., Olszanski, A.J., Luke, J.J., Balmanoukian, A.S., Kaufman, D.R., Zhao, Y., Maleski, J., Jones, M.J., Leopold, L., Gajewski, T.F.

Volltext

845P Vidutolimod + pembrolizumab as 2L+ treatment in patients with anti–PD-1–refractory melanoma and adrenal insufficiency: Subgroup analyses of a phase Ib study von Kirkwood, J.M., Zakharia, Y., Davar, D., Buchbinder, E., Medina, T., Daud, A., Ribas, A., Chmielowski, B., Niu, J.J., Gibney, G.T., Margolin, K.A., Olszanski, A.J., Mehmi, I., Sato, T., Shaheen, M., Zhao, L., Bobilev, D., Krieg, A.M., Wooldridge, J., Milhem, M.

Volltext

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer von Twelves, C., Chmielowska, E., Havel, L., Popat, S., Swieboda-Sadlej, A., Sawrycki, P., Bycott, P., Ingrosso, A., Kim, S., Williams, J.A., Chen, C., Olszanski, A.J., de Besi, P., Schiller, J.H.

Volltext

Donor-Derived Metastatic Melanoma and Checkpoint Inhibition von Boyle, S.M., Ali, N., Olszanski, A.J., Park, D.J., Xiao, G., Guy, S., Doyle, A.M.

Volltext

Phase I/II evaluation of intratumoral INT230-6 for the treatment of solid tumors von El-Khoeuiry, A., Siu, L.L., Azad, N., Walters, I.B., Bender, L., Kamen, L., Olszanski, A.J.

Volltext

Initial safety assessment of MAGE-A4 SPEAR T-cells von Hong, D.S., Butler, M.O., Johnson, M., Olszanski, A.J., Norry, E., Van Winkle, E., Chagin, K.D., Amado, R.G.

Volltext

1670O - ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma von Van Tine, B.A., Butler, M.O., Araujo, D., Johnson, M.L., Clarke, J., Liebner, D., Odunsi, K., Olszanski, A.J., Basu, S., Brophy, F., Holdich, T., Trivedi, T., Amado, R.G., Hong, D.S.

Volltext